Cover Image
Market Research Report

Global Erectile Dysfunction (ED) Drugs Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 312457
Published Content info 121 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Erectile Dysfunction (ED) Drugs Market 2019-2023
Published: March 27, 2019 Content info: 121 Pages
Description

About this market

The high prevalence of conditions resulting in ED is one of the key factors expected to trigger the market's growth in the forthcoming years. Various health conditions including diabetes, hypertension, obesity, depression, stress, and excessive alcohol consumption are resulting in the rising incidences of ED among elderly as well as young people. As these conditions directly alter the normal physiological levels of hormones, enzymes, and other factors, problems including penile erection have surged considerably in the recent years. These issues will further lead the erectile dysfunction drugs market to register a significant growth in the forthcoming years. Technavio's analysts have predicted that the erectile dysfunction (ED) drugs market will register a CAGR of over 4% by 2023.

Market Overview

Rising demand for ED drugs

One of the growth drivers of the global erectile dysfunction (ED) drugs market is the rising demand for ED drugs. The rising cyberpornography and the increasing number of advertisements for the treatment of ED are expected to propel the growth of the global erectile dysfunction (ED) drugs market during the forecast period.

Side effects of available drugs

One of the challenges in the growth of the global erectile dysfunction (ED) drugs market is the side effects of available drugs. The alterations in the blood flow, which are caused by ED drugs, result in side-effects such as headache, vision changes, and dizziness, which will hinder the growth of the market.

For the detailed list of factors that will drive and challenge the growth of the erectile dysfunction (ED) drugs market during 019-2023, view our report.

Competitive Landscape

The market appears to be moderately concentrated with the presence of a few market players. Many vendors in the market are focusing on expanding research for the development of novel therapies such as stem cells for the treatment of ED. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR31071

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Oral drugs - Market size and forecast 2018-2023
  • Topical drugs - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • VIVUS Inc.

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

PART 16: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline molecules for ED
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Oral drugs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Oral drugs - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Sales of VIAGRA and CIALIS 2016-2018
  • Exhibit 23: Topical drugs - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Topical drugs - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Market opportunity by product
  • Exhibit 28: Customer landscape
  • Exhibit 29: Market share by geography 2018-2023 (%)
  • Exhibit 30: Geographic comparison
  • Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Key leading countries
  • Exhibit 40: Market opportunity
  • Exhibit 41: Impact of drivers and challenges
  • Exhibit 42: Vendor landscape
  • Exhibit 43: Landscape disruption
  • Exhibit 44: Vendors covered
  • Exhibit 45: Vendor classification
  • Exhibit 46: Market positioning of vendors
  • Exhibit 47: Bayer AG - Vendor overview
  • Exhibit 48: Bayer AG - Business segments
  • Exhibit 49: Bayer AG - Organizational developments
  • Exhibit 50: Bayer AG - Geographic focus
  • Exhibit 51: Bayer AG - Segment focus
  • Exhibit 52: Bayer AG - Key offerings
  • Exhibit 53: Eli Lilly and Company - Vendor overview
  • Exhibit 54: Eli Lilly and Company - Business segments
  • Exhibit 55: Eli Lilly and Company - Organizational developments
  • Exhibit 56: Eli Lilly and Company - Geographic focus
  • Exhibit 57: Eli Lilly and Company - Segment focus
  • Exhibit 58: Eli Lilly and Company - Key offerings
  • Exhibit 59: Pfizer Inc. - Vendor overview
  • Exhibit 60: Pfizer Inc. - Business segments
  • Exhibit 61: Pfizer Inc. - Organizational developments
  • Exhibit 62: Pfizer Inc. - Geographic focus
  • Exhibit 63: Pfizer Inc. - Segment focus
  • Exhibit 64: Pfizer Inc. - Key offerings
  • Exhibit 65: Teva Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 66: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 67: Teva Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 68: Teva Pharmaceutical Industries Ltd. - Geographic focus
  • Exhibit 69: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibit 70: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 71: VIVUS Inc. - Vendor overview
  • Exhibit 72: VIVUS Inc. - Business segments
  • Exhibit 73: VIVUS Inc. - Organizational developments
  • Exhibit 74: VIVUS Inc. - Geographic focus
  • Exhibit 75: VIVUS Inc. - Key offerings
  • Exhibit 76: Validation techniques employed for market sizing
Back to Top